REFERENCES

management of cancer pain in adults and children. Glenview, IL: American Pain Society (APS) 2005. 166 p. Clinical practice guideline; no. 3. 3. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today 2004;9:697–703. 4. Skaer TL. Practice guidelines for transdermal opioids in malignant pain. Drugs 2004;64:2629–2638. 5. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice-a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 2005;21:1147–1156. 6. Bohme K. Buprenorphine in a transdermal therapeutic system—A new option. Clin Rheumatol 2002;21:S13–S16. 7. Michel E, Zernikow B. Buprenorphine in children. A clinical and pharmacological review. Schmerz 2006;20:40–50. 8. Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: A multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther 2006;28:943–952. 9. Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 2006;20:S25–S30. 10. Radbruch L. Buprenorphine TDS: Use in daily practice, benefits for patients. Int J Clin Pract Suppl 2003;133:19–22. 11. Zernikow B, Smale H, Michel E, et al. Paediatric cancer pain management using the WHO analgesic ladder-results of a prospective analysis from 2265 treatment days during a quality improvement study. Eur J Pain 2006;10:587–595. 12. Sittl R. Buprenorphine transdermal patch: Clinical expert report